Mineralys Therapeutics presented detailed results from its Phase 2 Advance-HTN trial at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) on March 29, 2025. The presentation highlighted lorundrostat's efficacy in patients with confirmed uncontrolled or resistant hypertension.
The data showed that lorundrostat 50 mg achieved a 15.4 mmHg absolute reduction and a 7.9 mmHg placebo-adjusted reduction in 24-hour ambulatory systolic blood pressure at week 12. This robust blood pressure lowering was observed in a high-risk patient population, including a significant proportion of underrepresented individuals.
Lorundrostat also demonstrated a favorable safety and tolerability profile, with modest and reversible changes in potassium, sodium, and eGFR, and a low discontinuation rate. These findings underscore the drug's potential as a well-tolerated, once-daily therapy for complex hypertension cases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.